Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

Makimoto, Go; Shimonishi, Atsushi; Ohashi, Kadoaki; Ninomiya, Kiichiro; Higo, Hisao; Kato, Yuka; Fujii, Masanori; Kubo, Toshio; Ichihara, Eiki; Hotta, Katsuyuki; Tabata, Masahiro; Maeda, Yoshinobu; Kiura, Katsuyuki

doi:10.1159/000524326

Permalink : https://ousar.lib.okayama-u.ac.jp/63969

ID	63969
FullText URL	fulltext.pdf 533 KB
Author	Makimoto, Go Department of Allergy and Respiratory Medicine, Okayama University Hospital Shimonishi, Atsushi Department of Allergy and Respiratory Medicine, Okayama University Hospital Ohashi, Kadoaki Department of Allergy and Respiratory Medicine, Okayama University Hospital ORCID Kaken ID researchmap Ninomiya, Kiichiro Department of Allergy and Respiratory Medicine, Okayama University Hospital Kaken ID Higo, Hisao Department of Allergy and Respiratory Medicine, Okayama University Hospital Kato, Yuka Center for Innovative Clinical Medicine, Okayama University Hospital Kaken ID Fujii, Masanori Department of Allergy and Respiratory Medicine, Okayama University Hospital Kubo, Toshio Center for Clinical Oncology, Okayama University Hospital Kaken ID researchmap Ichihara, Eiki Department of Allergy and Respiratory Medicine, Okayama University Hospital Kaken ID publons Hotta, Katsuyuki Center for Innovative Clinical Medicine, Okayama University Hospital Kaken ID publons researchmap Tabata, Masahiro Center for Clinical Oncology, Okayama University Hospital Kaken ID researchmap Maeda, Yoshinobu Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Kaken ID researchmap Kiura, Katsuyuki Department of Allergy and Respiratory Medicine, Okayama University Hospital ORCID Kaken ID publons researchmap
Abstract	Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx (R) Pan Lung Cancer polymerase chain reaction Panel (AmoyDx (R) panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx (R) panel and successfully treated with tepotinib. Although the patient's performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.
Keywords	MET Tepotinib Non-small-cell lung cancer
Published Date	2022
Publication Title	Case Reports In Oncology
Volume	volume15
Issue	issue2
Publisher	Karger
Start Page	494
End Page	498
ISSN	1662-6575
Content Type	Journal Article
language	English
OAI-PMH Set	岡山大学
Copyright Holders	© 2022 The Author(s).
File Version	publisher
PubMed ID	35702678
DOI	10.1159/000524326
Web of Science KeyUT	000864085100005
Related Url	isVersionOf https://doi.org/10.1159/000524326
License	https://creativecommons.org/licenses/by-nc/4.0/